BJOG-INT J OBSTET:长期服用二甲双胍或他汀类药物与癌症的关系

2018-02-28 佚名 Medicalxpress

根据发表于《国际妇产科杂志》上的一项研究,在患有2型糖尿病的女性中,没有发现二甲双胍或他汀类药物与卵巢癌发病率之间存在关联的证据。

根据发表于《国际妇产科杂志》上的一项研究,在患有2型糖尿病的女性中,没有发现二甲双胍或他汀类药物与卵巢癌发病率之间存在关联的证据。

近些年来,2型糖尿病成为了威胁人类整体健康的最大隐患之一,可怕的是,2型糖尿病的患病人数呈逐年上升的趋势。如果控制不当,2型糖尿病有可能会带来一系列可怕的并发症,这就意味着,糖尿病患者需要长期的服药。作为2型糖尿病的一级药物,二甲双胍是否会带来其他健康隐患一直是研究人员们关注的重点。

除此之外,继阿司匹林之后,他汀类药物也成为了人们日常预防血管疾病的一块基石,那么,长期服用他汀类药物与癌症有没有关联呢?

来自芬兰奥卢大学的研究人员利用国家登记簿,从1996年到2011年在芬兰发现了137643名女性(>40岁)被诊断为2型糖尿病。研究人员发现,303名妇女在随访期间被诊断为卵巢癌。与其他口服抗糖尿病药物相比,二甲双胍与卵巢癌的发病率无关。卵巢癌发病率与他汀类药物之间也没有关联。

研究人员表示:“没有发现使用二甲双胍或他汀类药物与2型糖尿病患者卵巢癌发病率之间的关联的证据,因此我们可以肯定的是,二甲双胍和他汀类药物的安全性很高,副作用相对较低。”

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2044495, encodeId=c058204449532, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed May 09 03:52:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780367, encodeId=c15e1e803671a, content=<a href='/topic/show?id=a5cd3502b5' target=_blank style='color:#2F92EE;'>#BJOG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3502, encryptionId=a5cd3502b5, topicName=BJOG)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc4b2500077, createdName=hittouch, createdTime=Thu Jun 28 00:52:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011375, encodeId=07ba20113e587, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Tue Jul 10 14:52:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291682, encodeId=cf5129168210, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Wed Feb 28 11:08:45 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2044495, encodeId=c058204449532, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed May 09 03:52:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780367, encodeId=c15e1e803671a, content=<a href='/topic/show?id=a5cd3502b5' target=_blank style='color:#2F92EE;'>#BJOG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3502, encryptionId=a5cd3502b5, topicName=BJOG)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc4b2500077, createdName=hittouch, createdTime=Thu Jun 28 00:52:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011375, encodeId=07ba20113e587, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Tue Jul 10 14:52:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291682, encodeId=cf5129168210, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Wed Feb 28 11:08:45 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
    2018-06-28 hittouch
  3. [GetPortalCommentsPageByObjectIdResponse(id=2044495, encodeId=c058204449532, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed May 09 03:52:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780367, encodeId=c15e1e803671a, content=<a href='/topic/show?id=a5cd3502b5' target=_blank style='color:#2F92EE;'>#BJOG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3502, encryptionId=a5cd3502b5, topicName=BJOG)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc4b2500077, createdName=hittouch, createdTime=Thu Jun 28 00:52:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011375, encodeId=07ba20113e587, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Tue Jul 10 14:52:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291682, encodeId=cf5129168210, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Wed Feb 28 11:08:45 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
    2018-07-10 yhy100200
  4. [GetPortalCommentsPageByObjectIdResponse(id=2044495, encodeId=c058204449532, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed May 09 03:52:00 CST 2018, time=2018-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780367, encodeId=c15e1e803671a, content=<a href='/topic/show?id=a5cd3502b5' target=_blank style='color:#2F92EE;'>#BJOG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3502, encryptionId=a5cd3502b5, topicName=BJOG)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc4b2500077, createdName=hittouch, createdTime=Thu Jun 28 00:52:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011375, encodeId=07ba20113e587, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Tue Jul 10 14:52:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291682, encodeId=cf5129168210, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Wed Feb 28 11:08:45 CST 2018, time=2018-02-28, status=1, ipAttribution=)]
    2018-02-28 139****5926

    好好文章学习了

    0

相关资讯

Psychother Psychosom:长期服用抗抑郁药物的情况会更糟

在当前的心理治疗和精神医学研究中,一项新的分析揭示了抗抑郁药物长期疗效的观点。重度抑郁症(MDD)在临床中比在社区样本中更常见或反复出现。例如,也许85%的患者,但只有35%的社区中重度抑郁症患者在15年内经历了另一种抑郁发作。尽管如此,包括抗抑郁药物或认知疗法在内的积极治疗可以减少抑郁症状,并延缓复发。然而,在临床试验中接受治疗和未经治疗的患者的随访时间很少超过1-2年。